Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Scott Okuno

Oncology | Hematology
Mayo Clinic
200 1st St Sw, 
Rochester, MN 
Offers Telehealth

Advanced in WT1-Related Wilms Tumor Syndromes
Mayo Clinic
200 1st St Sw, 
Rochester, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Scott Okuno is an Oncologist and a Hematologist in Rochester, Minnesota. Dr. Okuno is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Myxoid Liposarcoma, and Alveolar Soft Part Sarcoma.

His clinical research consists of co-authoring 99 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in WI
Hospital Affiliations
Mayo Clinic Health System-Franciscan Medical Center Inc
Mayo Clinic Health System Eau Claire Hospital
Mayo Clinic Hlth Systm Franciscan Hlthcare Sparta
Tamarack Health Hayward Medical Center
Mayo Clinic Health System In Red Wing
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Sanford
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Sanford Health
  • HMO
  • PPO
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

MAYO CLINIC
200 1st St Sw, Rochester, MN 55905
Call: 507-284-2511
Other Locations
MAYO CLINIC HEALTH SYSTEM-SOUTHWEST WISCONSIN REGION INC
800 E Blackhawk Ave, Prairie Du Chien, WI 53821
Call: 608-326-0808
MAYO CLINIC HEALTH SYSTEM-SOUTHEAST MINNESOTA REGION
701 Hewitt Blvd, Red Wing, MN 55066
Call: 651-267-5000
MAYO CLINIC HEALTH SYSTEM-SOUTHWEST WISCONSIN REGION INC
800 W Ave S, La Crosse, WI 54601
Call: 608-785-0940
MAYO CLINIC HEALTH SYSTEM-SOUTHEAST MINNESOTA REGION
404 W Fountain St, Albert Lea, MN 56007
Call: 507-373-2384

Additional Areas of Focus

Dr. Okuno has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


14 Clinical Trials

A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drug: MDM2 Inhibitor KRT-232
Study Phase: Phase 1
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other, Drug
Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
Enrollment Status: Active_not_recruiting
Publish Date: May 13, 2025
Intervention Type: Other, Drug
Study Drugs: Cabozantinib, Temozolomide
Study Phase: Phase 2
Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas
Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas
Enrollment Status: Active_not_recruiting
Publish Date: November 21, 2023
Intervention Type: Drug
Study Drugs: Seclidemstat, Cyclophosphamide, Topotecan
Study Phase: Phase 1
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A Phase 2 Trial of BN-Brachyury and Radiation Therapy in Patients With Advanced Chordoma
A Phase 2 Trial of BN-Brachyury and Radiation Therapy in Patients With Advanced Chordoma
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Biological
Study Drug: BN-Brachyury plus Radiation
Study Phase: Phase 2
Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck or Metastatic Breast Cancer
Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck or Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: February 14, 2023
Intervention Type: Other, Biological
Study Drug: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Study Phase: Phase 1
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
A Phase II Study of Pazopanib With Oral Topotecan in Patients With Metastatic and Non-resectable Soft Tissue and Bone Sarcomas
A Phase II Study of Pazopanib With Oral Topotecan in Patients With Metastatic and Non-resectable Soft Tissue and Bone Sarcomas
Enrollment Status: Completed
Publish Date: June 07, 2022
Intervention Type: Drug, Other
Study Drugs: Pazopanib Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Enrollment Status: Completed
Publish Date: April 25, 2022
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A Phase II Study of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
A Phase II Study of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Enrollment Status: Completed
Publish Date: August 05, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 13 Less Clinical Trials

99 Total Publications

Predicting Tolerance to Anthracycline Chemotherapy Using Electrocardiogram-Based Artificial Intelligence in Sarcoma.
Predicting Tolerance to Anthracycline Chemotherapy Using Electrocardiogram-Based Artificial Intelligence in Sarcoma.
Journal: Mayo Clinic proceedings. Digital health
Published: July 31, 2025
View All 99 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Elisabeth I. Heath
Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Elisabeth I. Heath
Oncology | Hematology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.1 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Elisabeth Heath is an Oncologist and a Hematologist in Rochester, Minnesota. Dr. Heath is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Orchiectomy. Dr. Heath is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Brian Costello
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Brian Costello
Hematology | Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.1 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Brian Costello is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Costello is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Nephrectomy, and Orchiectomy.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. David Marinier
Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. David Marinier
Hematology | Oncology

Gundersen Clinic Ltd

123 Se 5th Ave, 
Spring Grove, MN 
 (52.6 miles away)
507-498-3302
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Marinier is a Hematologist and an Oncologist in Spring Grove, Minnesota. Dr. Marinier is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Colorectal Cancer, and Lynch Syndrome.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Okuno's expertise for a condition
ConditionClose
  • Elite
  • Adult Soft Tissue Sarcoma
    Dr. Okuno is
    Elite
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Liposarcoma
    Dr. Okuno is
    Elite
    . Learn about Liposarcoma.
    See more Liposarcoma experts
  • Distinguished
  • Alveolar Soft Part Sarcoma
    Dr. Okuno is
    Distinguished
    . Learn about Alveolar Soft Part Sarcoma.
    See more Alveolar Soft Part Sarcoma experts
  • Angiosarcoma
    Dr. Okuno is
    Distinguished
    . Learn about Angiosarcoma.
    See more Angiosarcoma experts
  • Bone Tumor
    Dr. Okuno is
    Distinguished
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Epithelioid Sarcoma
    Dr. Okuno is
    Distinguished
    . Learn about Epithelioid Sarcoma.
    See more Epithelioid Sarcoma experts
  • Ewing Sarcoma
    Dr. Okuno is
    Distinguished
    . Learn about Ewing Sarcoma.
    See more Ewing Sarcoma experts
  • Fibrosarcoma
    Dr. Okuno is
    Distinguished
    . Learn about Fibrosarcoma.
    See more Fibrosarcoma experts
View All 18 Distinguished Conditions
  • Advanced
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Okuno is
    Advanced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Angiosarcoma of the Liver
    Dr. Okuno is
    Advanced
    . Learn about Angiosarcoma of the Liver.
    See more Angiosarcoma of the Liver experts
  • Breast Cancer
    Dr. Okuno is
    Advanced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Chondrosarcoma
    Dr. Okuno is
    Advanced
    . Learn about Chondrosarcoma.
    See more Chondrosarcoma experts
  • Clear Cell Sarcoma
    Dr. Okuno is
    Advanced
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Colorectal Cancer
    Dr. Okuno is
    Advanced
    . Learn about Colorectal Cancer.
    See more Colorectal Cancer experts
View All 23 Advanced Conditions
  • Experienced
  • Acute Myelomonocytic Leukemia
    Dr. Okuno is
    Experienced
    . Learn about Acute Myelomonocytic Leukemia.
    See more Acute Myelomonocytic Leukemia experts
  • Adult Immune Thrombocytopenia
    Dr. Okuno is
    Experienced
    . Learn about Adult Immune Thrombocytopenia.
    See more Adult Immune Thrombocytopenia experts
  • Agranulocytosis
    Dr. Okuno is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Ampullary Cancer
    Dr. Okuno is
    Experienced
    . Learn about Ampullary Cancer.
    See more Ampullary Cancer experts
  • Anemia
    Dr. Okuno is
    Experienced
    . Learn about Anemia.
    See more Anemia experts
  • Angiosarcoma of the Scalp
    Dr. Okuno is
    Experienced
    . Learn about Angiosarcoma of the Scalp.
    See more Angiosarcoma of the Scalp experts
View All 105 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved